Interestingly, given that ICI achieves complete remissions in no more than 15% of the patients yet the survival curves of patients receiving CTLA-4-as well as PD-1 blockade-based therapies flatten after 3 to 4 years for a sizeable fraction (a respectable third) of the patients, it is tempting to argue that we are seeing something unique that can be best described as “the containment of cancer”. This evidence concerns the gene CTLA4 and cancer.